| Hazard Information | Back Directory | [History]
Donanemab, developed by Eli Lilly and Company, is a monoclonal antibody used for the treatment of Alzheimer's disease. In July 2024, the U.S. Food and Drug Administration (FDA) has effectively approved the Kisunla (donanemab-azbt) injection for the treatment of AD in patients with mild cognitive impairment or mild dementia, in which the drugs were tested in clinical trials. Kisunla is given intravenously, and the recommended dose is given every 4 weeks. | [Uses]
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2]. | [References]
[1] Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. DOI:10.1002/trc2.12112
[2] Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. DOI:10.1056/NEJMoa2100708 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|